ASH 2025 | Patient-reported outcomes in the Phase III VERIFY trial of rusfertide for polycythemia vera

This is the Phase III study on hepcidin mimetic rusfertide for patients with polycythemia vera. We met all the primary endpoints at week 32 and also all the secondary endpoints at week 32. This abstract on the patient-reported outcomes details out the results of the secondary outcomes looking at patient-reported outcomes specifically. So, essentially looking at the PROMIS Fatigue 8a scores and the MF-SAF scores which are focused on improvement in patient-reported or patient quality of life. So, what we found that patients who got rusfertide as compared to placebo had a significant improvement in the fatigue score as seen by the change in the PROMIS Fatigue 8a score and also in the overall symptom burden as was seen by the MF-SAF version 4 score. Not only that, when we looked at what does this all mean clinically, does the patient feel different. So, we looked at the clinically meaningful change in every patient and we found that in the rusfertide arm, almost over 40, 41 patients reported a meaningfully increased or improved change in their health status as compared to same or worsened with the placebo arm. So overall we found that the study met its primary and secondary endpoints and as this abstract details out about the focus or focuses on the patient-reported outcomes and shows that the rusfertide helps improve patient-reported outcomes as compared to placebo.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.